Acute lymphoblastic leukemia and Down syndrome: Presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)

Cancer

Volumn 113, Issue 3, 2008, Pages 515-521

  Arico, Maurizio ^a   Ziino, Ottavio ^b   Valsecchi, Maria Grazia ^c   Cazzaniga, Giovanni ^d   Baronci, Carlo ^e   Messina, Chiara ^f   Pession, Andrea ^g   Santoro, Nicola ^h   Basso, Giuseppe ^f   Conter, Valentino ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b G Di Cristina Children's Hospital   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF BARI   (Italy)

Author keywords

BFM chemotherapy; Childhood acute lymphoblastic leukemia; DNA index; Down syndrome

Indexed keywords

HYBRID PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GENETIC TRANSCRIPTION; HIGH RISK POPULATION; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DOWN SYNDROME; FEMALE; HUMANS; INFANT; ITALY; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49049105472     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23587     Document Type: Article

References (26)

1. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome [review]. Lancet Oncol. 2001;2:429-436.
2. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169.
3. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512-524.
4. Robison LL, Nesbit ME Jr, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr. 1984;105:235-242.
5. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child. 1990;65:212-216.
6. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia. 1998;12:645-651.
7. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321-325.
8. Whitlock JA, Sather HN, Gaynon R et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106:4043-4049.
9. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282.
10. Craze JL, Harrison G, Wheatley K, Hann IM, Chessells JM. Improved outcome of acute myeloid leukaemia in Down's syndrome. Arch Dis Child. 1999;81:32-37.
11. Stiller CA, Eatock EM. Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Arch Dis Child. 1999;81:202-208.
12. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128:797-804.
13. Kalwinsky DK, Raimondi SC, Bunin NJ, et al. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl. 1990;7:267-271.
14. Pui CH, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993;11:1361-1367.
15. Vecchi V, Arico M, Basso G, et al. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies. Cancer. 1993;72:2517-2524.
16. Paolucci G, Vecchi V, Favre C, et al. Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica. 2001;86:478-484.
17. Conter V, Arico M, Valsecchi MG, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt- Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol. 1995;13:2497-2502.
18. Conter V, Arico M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica. 1998;83:791-799.
19. Arico M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster- based chemotherapy. J Clin Oncol. 2008;26:283-289
20. Conter V, Schrauder A, Gadner H, et al. Impact of minimal residual disease (MRD) on prognosis in children with acute lymphoblastic leukemia (ALL) according to WBC count, age and TEL/AML1 status at diagnosis. Results of the AIEOP-BFM ALL 2000 study. Presented at: ASH Meeting 2007.
21. Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982- 1995. Leukemia. 2000;14:2196-2204.
22. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
23. Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AMLl-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006;107:4508-4513.
24. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571-577.
25. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111:1575-1583.
26. Izraeli S, Rainis L, Hertzberg L, Smooha G, Birger Y. Trisomy of chromosome 21 in leukemogenesis [review]. Blood Cells Mol Dis. 2007;39:156-159.